Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Part of paid clinical trials in La Jolla, California.

Sponsor
Hitendra Patel
Study ID
NCT03697564
Phase
PHASE2
Status
Completed

Conditions

  • Pancreatic Cancer Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.

Key Dates

Start date
Oct 31, 2019
Status verified
Jul 2025
Primary completion
Apr 12, 2023
Completion
Jul 13, 2023

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: gemcitabine +nivolumab + cabiralizumab
    gemcitabine +nivolumab + cabiralizumab

Primary Outcome Measure

Number of Participants With Progression Free Survival (PFS) [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-

Related coverage on Hipa.ai

Find similar trials in La Jolla, CA

By research site
UCSD Moores Cancer Center· La Jolla, CA

Related Studies